Using organoids to predict chemotherapy response in osteosarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine the sensitivity of osteosarcoma to various chemotherapy agents by utilizing tissue cultures in the laboratory. Researchers will establish organoids from tumor samples obtained during routine biopsies or surgeries, allowing for the assessment of how these organoids respond to different treatments. The study will also incorporate genetic testing to enhance understanding of osteosarcoma and its treatment responses. The innovative miniaturized system developed allows for efficient testing of multiple drug combinations and treatment protocols on these organoids.

Why it matters

Who can join: the full rules

Inclusion / exclusion criteria - Group1:

\- Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes

Inclusion / exclusion criteria - Group 2:

\- Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes

Where it's running

• UCLA / Jonsson Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Alice Soragni, PhD — University of California at Los Angeles
• Study coordinator: Summer Swearingen
• Email: SSwearingen@mednet.ucla.edu
• Phone: (424) 766-9349

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Immunotherapy plus standard treatment for high-risk osteosarcoma in kids and young adults

  This study tests mifamurtide added to standard chemotherapy versus standard treatment with sorafenib to see if the combination helps patients with high-risk osteosarcoma.

  Recruiting Phase 2 Institute of Mother and Child, Warsaw, Poland · Warsaw, Mazovian · NCT07787429

• 68Ga-B7-H3 Nanobody PET Imaging in Osteosarcoma

  This study tests a new gallium-68 labeled B7-H3 nanobody to see if it can image osteosarcoma tumors more clearly.

  Recruiting Early Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT07774533

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Neoantigen Vaccine SarVac With Tumor-Specific Lymphocytes Plus PD-1 Blocker for Advanced Sarcoma

  This trial tests a personalized cancer vaccine called SarVac, given with a PD-1 blocker, and possibly tumor-specific lymphocytes, to see if it is safe and can help people with advanced soft tissue or bone sarcoma.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07648069

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.